Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Christoph

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Oncology Research and Treatment|April 18, 2019
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung CancerFrederik Krefting, Nadezda Basara, Wolfgang Schütte, et al.
Organic Letters|September 26, 2008
Enantiopure 2-substituted glyceraldehyde derivatives by aza-Claisen rearrangement or C-alkylation of enaminesKaty L Bridgwood, C Christoph Tzschucke, Matthew O'Brien, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)Martin Faehling, Christian Schumann, Petros Christopoulos, et al.
Data in Brief|December 28, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAPMartin Faehling, Christian Schumann, Petros Christopoulos, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 14, 2020
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaJustin Ferdinandus, Francesco Barbato, Michal Chodyla, et al.
Future Oncology (London, England)|July 21, 2021
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinomaMartin Metzenmacher, Filippo Rizzo, Kato Kambartel, et al.
Journal of Cancer|June 25, 2014
Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesisFabian D Mairinger, Robert F H Walter, Robert Werner, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2010
ADC changes in schizophrenia: a diffusion-weighted imaging studyIgor Nenadic, Gerd Wagner, Daniel Güllmar, et al.
Future Oncology (London, England)|June 20, 2014
Mdm2 protein expression is strongly associated with survival in malignant pleural mesotheliomaFabian D Mairinger, Robert F H Walter, Saskia Ting, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Oncology Research and Treatment|April 18, 2019
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung CancerFrederik Krefting, Nadezda Basara, Wolfgang Schütte, et al.
Organic Letters|September 26, 2008
Enantiopure 2-substituted glyceraldehyde derivatives by aza-Claisen rearrangement or C-alkylation of enaminesKaty L Bridgwood, C Christoph Tzschucke, Matthew O'Brien, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)Martin Faehling, Christian Schumann, Petros Christopoulos, et al.
Data in Brief|December 28, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAPMartin Faehling, Christian Schumann, Petros Christopoulos, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 14, 2020
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaJustin Ferdinandus, Francesco Barbato, Michal Chodyla, et al.
Future Oncology (London, England)|July 21, 2021
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinomaMartin Metzenmacher, Filippo Rizzo, Kato Kambartel, et al.
Journal of Cancer|June 25, 2014
Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesisFabian D Mairinger, Robert F H Walter, Robert Werner, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2010
ADC changes in schizophrenia: a diffusion-weighted imaging studyIgor Nenadic, Gerd Wagner, Daniel Güllmar, et al.
Future Oncology (London, England)|June 20, 2014
Mdm2 protein expression is strongly associated with survival in malignant pleural mesotheliomaFabian D Mairinger, Robert F H Walter, Saskia Ting, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
Pageof 11